Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H22N6O |
| Molecular Weight | 386.4497 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C2C(=NC=N1)N(N=C2C3=CC=C(OC4=CC=CC=C4)C=C3)[C@@H]5CCCNC5
InChI
InChIKey=GPSQYTDPBDNDGI-MRXNPFEDSA-N
InChI=1S/C22H22N6O/c23-21-19-20(15-8-10-18(11-9-15)29-17-6-2-1-3-7-17)27-28(22(19)26-14-25-21)16-5-4-12-24-13-16/h1-3,6-11,14,16,24H,4-5,12-13H2,(H2,23,25,26)/t16-/m1/s1
(R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine is a chemical precursor of BTK inhibitor ibrutinib and related compounds. (R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine lacks the propenamide group that is responsible for covalent binding to cysteine residue of BTK kinase.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. | 2015 Dec 24 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
58223272
Created by
admin on Sat Dec 16 19:04:34 GMT 2023 , Edited by admin on Sat Dec 16 19:04:34 GMT 2023
|
PRIMARY | |||
|
1022150-12-4
Created by
admin on Sat Dec 16 19:04:34 GMT 2023 , Edited by admin on Sat Dec 16 19:04:34 GMT 2023
|
PRIMARY | |||
|
NR6GN4MC2R
Created by
admin on Sat Dec 16 19:04:34 GMT 2023 , Edited by admin on Sat Dec 16 19:04:34 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
